Biomeme
Launched in 2012 by a handful of innovators, Biomeme employs over 120 people and is headquartered in downtown Philadelphia. For more than a decade, Biomeme has been designing and building molecular detection solutions, particularly its handheld, flagship device – Franklin® three9 Thermocycler’s -- with a focus on protecting the warfighter from bio-warfare agents and contaminants, the fight against anti-microbial resistance, and pandemic response against COVID-19. More broadly, Biomeme holds nine (9) global patents centered on the development and deployment of fast, accurate, and sensitive portable devices that utilize polymerase chain
reaction (PCR) and isothermal assays to detect targets, including bacterial and viral microorganisms, that include
diverse use cases from biowarfare agent panels to food safety, water quality, industrial quality control, vector
surveillance, environmental DNA (eDNA), animal health, and most recently human diagnostics with our FDA EUA
SARS-CoV-2 tests.
The Philadelphia HQ houses vertically integrated operations including assay and device R&D, software development, hardware & consumables manufacturing, PCR assay lyophilization, and even diagnostic testing services through our wholly-owned CLIA high-complexity lab network. Additionally, due to the COVID pandemic, Biomeme took the extra step to onshore the majority of its supply chain and, again, manufacture its products in Philadelphia. With a robust civilian market, Biomeme has also successfully partnered with the Department of Defense on several RDT&E opportunities to enhance the Franklin device, particularly with the U.S. Special Operations Command (SOCOM) and the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), that have evolved into official programs of record for the Franklin device – 1) The Joint Handheld Bio-Agent Identifier (JHBI) and 2) The Joint Biological Tactical Detection System (JBTDS).